Neuropathic cancer pain in patients treated with an EGFR-inhibitor

CONTEXT: Novel treatments of neuropathic pain (NP) are urgently needed. Based on repeated observation of rapid relief of neuropathic cancer pain (NCP) after single doses of intravenous epidermal growth factor receptor inhibitor (EGFR-I), we have successfully treated patients with and without cancer who suffer from severe, treatment-refractory NP with EGFR-Is. Pain research is complicated by endpoint subjectivity. Patients with advanced cancer are heterogeneous, with complex, fluctuating clinical pictures, hampering feasibility of standard drug-trial procedures.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research